Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PLX 
Protalix Biotherapeutics Inc (PLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: PLX (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 233.57% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 198.20M USD | Price to earnings Ratio 63.5 | 1Y Target Price 14.5 |
Price to earnings Ratio 63.5 | 1Y Target Price 14.5 | ||
Volume (30-day avg) 647691 | Beta 0.72 | 52 Weeks Range 0.82 - 2.76 | Updated Date 04/1/2025 |
52 Weeks Range 0.82 - 2.76 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate 0.07 | Actual 0.09 |
Profitability
Profit Margin 5.49% | Operating Margin (TTM) 39.57% |
Management Effectiveness
Return on Assets (TTM) 3.1% | Return on Equity (TTM) 7.64% |
Valuation
Trailing PE 63.5 | Forward PE 8.32 | Enterprise Value 168898768 | Price to Sales(TTM) 3.77 |
Enterprise Value 168898768 | Price to Sales(TTM) 3.77 | ||
Enterprise Value to Revenue 3.22 | Enterprise Value to EBITDA 26.38 | Shares Outstanding 78032600 | Shares Floating 59149480 |
Shares Outstanding 78032600 | Shares Floating 59149480 | ||
Percent Insiders 13.7 | Percent Institutions 6.03 |
Analyst Ratings
Rating - | Target Price 14 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Protalix Biotherapeutics Inc
Company Overview
History and Background
Protalix Biotherapeutics Inc. was founded in 1993. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced by its ProCellEx plant cell-based protein expression system. A significant milestone was the FDA approval of Elelyso, its first product.
Core Business Areas
- Enzyme Replacement Therapies: Focuses on developing and commercializing enzyme replacement therapies for genetic disorders.
- Plant Cell-Based Protein Expression: Utilizes its proprietary ProCellEx platform to produce recombinant therapeutic proteins.
Leadership and Structure
The leadership team includes key executives in research and development, commercial operations, and finance. The organizational structure is typical of a biotechnology company, with departments dedicated to research, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Elelyso (taliglucerase alfa): An enzyme replacement therapy for Gaucher disease. Market share data is variable but Protalix faces competition from Sanofi (GENZ) and Takeda (TAK). Revenue varies year to year. Competitors include Cerezyme and VPRIV.
- Pegunigalsidase alfa: An enzyme replacement therapy for Fabry disease.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for enzyme replacement therapies is driven by the prevalence of genetic disorders and the availability of effective treatments.
Positioning
Protalix is a niche player in the biopharmaceutical industry, focusing on enzyme replacement therapies using its proprietary plant cell-based protein expression system. Its competitive advantage lies in the potential for lower manufacturing costs and improved product characteristics.
Total Addressable Market (TAM)
The total market value of enzyme replacement therapies is estimated to be several billion dollars annually. Protalix is positioned to capture a portion of this market through its existing products and pipeline candidates.
Upturn SWOT Analysis
Strengths
- Proprietary ProCellEx platform
- Approved product (Elelyso)
- Pipeline of enzyme replacement therapies
Weaknesses
- Limited financial resources
- Reliance on partnerships for commercialization
- Competition from larger pharmaceutical companies
Opportunities
- Expansion into new markets
- Development of new enzyme replacement therapies
- Strategic collaborations
Threats
- Regulatory challenges
- Competition from biosimilars
- Clinical trial failures
Competitors and Market Share
Key Competitors
- SNY
- TAK
Competitive Landscape
Protalix faces intense competition from larger pharmaceutical companies with greater resources. Its advantage lies in its proprietary technology and focus on specific niche markets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to the nature of the biopharmaceutical industry.
Future Projections: Future growth depends on the success of its pipeline candidates and the expansion of its existing products. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include the development of new enzyme replacement therapies and strategic partnerships.
Summary
Protalix is a biopharmaceutical company with a focus on enzyme replacement therapies using its proprietary ProCellEx platform. Elelyso is its main source of revenue, but it faces stiff competition. The company's success hinges on pipeline progress and partnerships, which can significantly fluctuate its financial performance. They need to watch out for competition biosimilars and clinical trial failures.
Similar Companies
- SNY
- TAK
- RDHL
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protalix Biotherapeutics Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 1998-05-15 | President, CEO & Director Mr. Dror Bashan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | Website https://www.protalix.com |
Full time employees 213 | Website https://www.protalix.com | ||
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.